Valsartan dosage 80 mg
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Valsartan Dosage 80 mg: Pharmacokinetics, Efficacy, and Clinical Applications
Pharmacokinetics and Bioequivalence of Valsartan 80 mg
Valsartan, an angiotensin II receptor blocker (ARB), is commonly prescribed for hypertension and heart failure. A study comparing the bioequivalence of two formulations of valsartan 80 mg capsules in healthy Chinese volunteers under fasting and fed conditions found that both formulations met the bioequivalence criteria. The geometric mean ratios (GMRs) for Cmax, AUC0-t, and AUC0-∞ were within the acceptable range, indicating similar pharmacokinetic profiles. Another study in Algerian volunteers also confirmed the bioequivalence of two brands of valsartan 80 mg tablets, although the Cmax did not fall within the strict bioequivalence range.
Efficacy of Valsartan 80 mg in Hypertension
Comparison with Other Antihypertensive Agents
A randomized trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension found that telmisartan was more effective in reducing diastolic blood pressure during the last 6 hours of the dosing interval. However, both medications were well-tolerated and showed significant blood pressure reductions. Another study comparing the efficacy of low-dose fimasartan (30 mg) with valsartan (80 mg) demonstrated that both drugs significantly reduced 24-hour systolic blood pressure, with no significant difference in tolerability.
Long-Term Blood Pressure Control
Valsartan 80 mg has been shown to provide effective 24-hour blood pressure control. A study using ambulatory blood pressure monitoring (ABPM) demonstrated significant reductions in both systolic and diastolic blood pressure over a 24-hour period, with consistent efficacy during both day and night. This makes valsartan a reliable option for sustained blood pressure management.
Clinical Applications in Heart Failure and Coronary Artery Disease
Heart Failure
In patients with chronic heart failure, valsartan 80 mg daily has been shown to significantly reduce levels of brain natriuretic peptide (BNP), aldosterone (ALD), and angiotensin II (Ang II), while improving left ventricular ejection fraction (LVEF). Higher doses (160 mg twice daily) were even more effective in reversing ventricular remodeling and improving cardiac function compared to conventional doses and benazepril.
Coronary Artery Disease
For patients with type B2/C coronary artery lesions, low-dose valsartan (80 mg/day) was initially found to have a high restenosis rate. However, increasing the dose to 160-320 mg/day significantly reduced angiographic restenosis rates, target lesion revascularization (TLR), and major adverse cardiac events (MACE).
Conclusion
Valsartan 80 mg is a well-tolerated and effective medication for managing hypertension and heart failure. It provides consistent 24-hour blood pressure control and has been shown to be bioequivalent across different formulations. While it is effective at the 80 mg dose, higher doses may offer additional benefits in specific clinical scenarios such as heart failure and coronary artery disease.
Sources and full results
Most relevant research papers on this topic